Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Vyloy Approved for Gastric, GEJ Cancer
FDA approves Vyloy (zolbetuximab-clzb) with fluoropyrimidine- and platinum-based chemo for first-line treatment of locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. Supported by phase 3 trials GLOW and SPOTLIGHT, Vyloy improved progression-free and overall survival. Common adverse events include nausea, vomiting, fatigue, and diarrhea. Vyloy is supplied as a 100 mg lyophilized powder for intravenous infusion.
Related Clinical Trials:
Survival and Treatment Patterns in Stage II to III Esophageal Cancer
Neoadjuvant chemoradiation with surgical resection improves survival in locally advanced esophageal cancer compared to definitive chemoradiation or radiotherapy alone.
Astellas' gastric cancer therapy approved in US
FDA approves VYLOY (zolbetuximab-clzb) for first-line treatment of CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma, in combination with chemotherapy. VYLOY is the first CLDN18.2-targeted therapy in the U.S., approved based on Phase 3 SPOTLIGHT and GLOW trials showing improved PFS and OS. Common side effects include nausea, vomiting, and decreased appetite.
Zolbetuximab-clzb Receives FDA Approval for Treatment of Advanced Gastric and GEJ
Zolbetuximab-clzb (Vyloy; Astellas Pharma Inc) received FDA approval for treating locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. Based on phase 3 SPOTLIGHT and GLOW trials, zolbetuximab-clzb demonstrated progression-free survival benefits in combination with chemotherapy regimens. This marks the first CLDN18.2-targeted therapy for this patient population.
Related Clinical Trials:
FDA Approves Zolbetuximab in Advanced CLDN18.2+ Gastric/GEJ Adenocarcinoma
FDA approves zolbetuximab-clzb (Vyloy) plus chemotherapy for HER2-negative, Claudin 18.2-positive gastric/gastroesophageal junction adenocarcinoma, supported by phase 3 SPOTLIGHT and GLOW trials showing PFS benefits.
Related Clinical Trials:
Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer
FDA approves zolbetuximab (Vyloy) as first-line treatment for HER2-negative, CLDN18.2-positive gastric/GEJ adenocarcinoma, following resubmission after CRL. Supported by phase 3 SPOTLIGHT and GLOW studies, zolbetuximab showed improved PFS in combination with mFOLFOX6 and CAPOX.
Related Clinical Trials:
Researchers Develop 3D-Printed Medication To Treat Deadly Infection In Pediatric Patients
Texas A&M University researchers develop 3D-printed medication for pediatric toxoplasmosis, addressing the high cost and lack of dose flexibility in current treatments. Funded by NIH, the project aims to create a novel dose-flexible pediatric delivery system, potentially easing burdens on parents and improving treatment availability.
A standing platform for cancer drug development using ctDNA-based evidence of recurrence
Article references various studies on cancer trends, clinical trials, and molecular residual disease detection using circulating tumor DNA, highlighting their implications for cancer treatment and management.
Related Clinical Trials:
Sensitizing pancreatic cancer to immunotherapy
Immunotherapy struggles against pancreatic ductal adenocarcinoma (PDAC) due to CXCL12 protein repelling T cells. A study by Jiayun Li and colleagues found that natural killer T (NKT) cells and type I interferons could remodel the immunosuppressive microenvironment, allowing T cells to penetrate and enhance immunotherapy. Folinic acid, used to boost NKT cells, showed promise when combined with anti-PD-1 antibodies in mice, though human trials are needed to confirm efficacy.
Astellas' Vyloy combination approved by EC as first-line gastric cancer treatment
Astellas Pharma’s Vyloy (zolbetuximab) approved by EC for first-line treatment of claudin 18.2-positive, HER2-negative gastric/GEJ adenocarcinoma, alongside chemotherapy. Vyloy, administered every 2-3 weeks, is the first EU therapy targeting claudin 18.2-expressing tumour cells, supported by phase 3 SPOTLIGHT and GLOW trial results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath